Subject: Re: Collaboration on Project Seraphim

---

From: Breanna Edwards <angela26@example.org>  
Sent: Thursday, October 5, 2023, 10:14 AM  
To: Christine Rosales <darrellmeyers@example.org>  
Subject: Re: Collaboration on Project Seraphim

Hi Christine,

Thanks for getting back to me so quickly. I completely understand the need for detailed updates; precision is key in ensuring compliance and successful outcomes. I’ll make sure to include the latest assay data and analysis from our recent trials in my report. 

Regarding the timeline, I am aiming to have the finalized data package ready by October 20th. I will loop in Dr. Patel from the pharmacokinetics team, as his insights could be invaluable for the upcoming review meeting. 

Also, I noticed the preliminary results from the immunogenicity study were uploaded to the shared drive. They look promising, and I believe they’ll complement our findings well. 

Let’s aim to touch base early next week. How does Tuesday at 2 PM work for you? We can meet at the conference room on the 5th floor if that’s convenient.

Best,  
Breanna  
(555) 014-5678

---

From: Christine Rosales <darrellmeyers@example.org>  
Sent: Wednesday, October 4, 2023, 3:42 PM  
To: Breanna Edwards <angela26@example.org>  
Subject: Collaboration on Project Seraphim

Hi Breanna,

I hope this message finds you well. I wanted to discuss the current status of Project Seraphim, particularly your recent findings on the biomarker analysis. As you know, our next regulatory submission deadline is approaching fast, and having an updated report would be crucial for our compliance documentation.

Could you provide me with a brief update on your progress? It would be great to include any insights from the latest clinical data integration. Additionally, let's coordinate with the regulatory affairs team to ensure alignment.

Please let me know your availability for a meeting next week. This would also give us a chance to prepare for the upcoming internal review scheduled for October 25th.

Looking forward to your response.

Best regards,  
Christine Rosales  
Clinical Research Associate  
Merck & Co.  
(555) 987-4321